{"entity":{"id":"halozyme","kind":"company","name":"Halozyme Therapeutics","aka":["Halozyme Therapeutics, Inc.","Halozyme"],"tldr":"Halozyme's recombinant hyaluronidase (ENHANZE) is what lets antibodies such as rituximab, trastuzumab and daratumumab be given as quick under-the-skin injections instead of long infusions; its own tumour-targeting version failed in pancreatic cancer.","summary":"Halozyme Therapeutics, founded in 1998 in San Diego, licenses its ENHANZE drug-delivery technology, a recombinant human hyaluronidase that breaks down hyaluronan under the skin so large volumes of antibody can be injected subcutaneously; the subcutaneous forms of rituximab, trastuzumab, daratumumab, pertuzumab and atezolizumab rely on it. Its own PEGylated hyaluronidase PEGPH20, aimed at hyaluronan-rich pancreatic tumours, failed the phase 3 HALO-301 trial in 2019. ClinicalTrials.gov lists Halozyme as lead sponsor of that and other phase 3 trials.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.halozyme.com"},{"label":"ClinicalTrials.gov: trials led by Halozyme Therapeutics, Inc.","url":"https://clinicaltrials.gov/search?lead=Halozyme%20Therapeutics%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q5643474"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["rituximab","trastuzumab","daratumumab"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://www.halozyme.com","founded":1998,"stage":"public","investors":[],"funding":[]},"route":"/companies/halozyme/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"term":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/"}]}}